Bank Of New York Mellon Corp Vaxcyte, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $6.33 Million - $14.8 Million	307,648 New	307,648 $14.8 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $509,563 - $670,255	23,493 Added 15.05%	179,570 $4.31 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $65,645 - $98,691	3,713 Added 2.44%	156,077 $3.4 Million
Q1 2022 May 11, 2022	BUY	$17.46 - $26.36 $120,316 - $181,646	6,891 Added 4.74%	152,364 $3.68 Million
Q4 2021 Feb 11, 2022	BUY	$19.32 - $26.45 $152,145 - $208,293	7,875 Added 5.72%	145,473 $3.46 Million
Q3 2021 Nov 12, 2021	BUY	$20.26 - $26.97 $386,803 - $514,911	19,092 Added 16.11%	137,598 $3.49 Million
Q2 2021 Aug 11, 2021	BUY	$16.45 - $24.06 $553,855 - $810,076	33,669 Added 39.69%	118,506 $2.67 Million
Q1 2021 May 13, 2021	BUY	$18.66 - $29.16 $352,618 - $551,036	18,897 Added 28.66%	84,837 $1.68 Million
Q4 2020 Feb 09, 2021	BUY	$26.57 - $51.74 $343,417 - $668,739	12,925 Added 24.38%	65,940 $1.75 Million
Q3 2020 Nov 12, 2020	BUY	$26.5 - $55.4 $1.4 Million - $2.94 Million	53,015 New	53,015 $2.62 Million

353

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.86B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.